CVS Health in a new white paper outlines four key approaches health plans and plan sponsors can take to help cushion the blow of high-cost gene therapies, Fierce Healthcare reports.
In its report, CVS outlines the following four steps:
- Extending the National Medical Excellence program model;
- Evolving the role of specialty pharmacy;
- Value-based contracting; and
- Financial protection programs.
To read CVS Health’s white paper, click here.